Citi Pharma Maintains Steady Profit in 1QFY26 Despite Rising Financial Costs
Citi Pharma Limited posted a profit after tax of Rs203.69 million for 1QFY26, marking a 1% rise from last year. While higher finance costs and reduced other income pressured margins, improved gross profit and lower taxation helped sustain steady earnings.
Dynea Pakistan Limited Eyes Export Expansion Amidst Financial Fluctuations
Dynea Pakistan Limited (PSX: DYNO) navigates financial challenges with strategic export expansion and operational efficiencies, aiming for growth in volatile markets.